Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humanss

Drug Metabolism and Disposition

Volumn 41, Issue 5, 2013, Pages 1046-1059

  Dingemanse, Jasper ^a   Hoever, Petra ^a   Hoch, Matthias ^a   Treiber, Alexander ^b   Wagner Redeker, Winfried ^c   Miraval, Tommaso ^c   Hopfgartner, Gérard ^c   Shakeri Nejad, Kasra ^a  

^a Department of Clinical Pharmacology ^*  (Switzerland)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c Swiss BioAnalytics AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOREXANT; CARBON 14; DRUG METABOLITE; GLUCURONIC ACID; ISOQUINOLINE DERIVATIVE; PHENOL DERIVATIVE; PHENYLGLYCINE; SULFONIC ACID DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEALKYLATION; DEMETHYLATION; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; STRUCTURE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ACETAMIDES; ADMINISTRATION, ORAL; ADULT; CHROMATOGRAPHY, LIQUID; HALF-LIFE; HUMANS; ISOQUINOLINES; MALE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; TANDEM MASS SPECTROMETRY;

ANIMALIA;

EID: 84876766162     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050120     Document Type: Article

References (21)

1. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, and de Haas SL, et al. (2007) Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 13:150-155.
2. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, and Kisanuki Y, et al. (1999) Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 98:437-451.
3. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, and Bartlett FS, 2nd, et al. (1998) The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95:322-327.
4. U.S. Food and Drug Administration (FDA) (2008) FDA guidance for industry. Safety testing of drug metabolites. Bethesda, MD: U.S. Department of Health and Human Services. February 2008.
5. Hoch M, Hoever P, Zisowsky J, Priestley A, Fleet D, and Dingemanse J (2012) Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects. Pharmacology 89:53-57.
6. Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, and Dingemanse J (2012a) Orexin receptor antagonism: An ascending multiple-dose study with almorexant. J Psychopharmacol 26:1071-1080.
7. Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, and Dingemanse J (2010) Orexin receptor antagonism, a new sleep-promoting paradigm: An ascending single-dose study with almorexant. Clin Pharmacol Ther 87:593-600.
8. Hoever P, Dorffner G, Benes H, Penzel T, Danker-Hopfe H, Barbanoj MJ, Pillar G, Saletu B, Polo O, and Kunz D, et al. (2012b) Orexin receptor antagonism, a new sleep-enabling paradigm: A proof-of-concept clinical trial. Clin Pharmacol Ther 91:975-985 .
9. International Conference on Harmonisation (ICH) (2009) Topic M3(R2). Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceutical products. CPMP/ICH/286/95. June 2009.
10. Kiyashchenko LI, Mileykovskiy BY, Maidment N, Lam HA, Wu MF, John J, Peever J, and Siegel JM (2002) Release of hypocretin (orexin) during waking and sleep states. J Neurosci 22:5282-5286.
11. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, and Mignot E (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:365-376.
12. National Institutes of Health (2005) National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 28:1049-1057.
13. Nishino S (2007) The hypocretin/orexin receptor: Therapeutic prospective in sleep disorders. Expert Opin Investig Drugs 16:1785-1797.
14. Nishino S, Ripley B, Overeem S, Lammers GJ, and Mignot E (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39-40.
15. Piper DC, Upton N, Smith MI, and Hunter AJ (2000) The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 12:726-730.
16. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, and Wilson S, et al. (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573-585.
17. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, Nishino S, and Mignot E (2003) Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry 54:96-104.
18. Sifton DW, editor (1995) Physicians' Desk Reference (PDR) Medical Dictionary, Williams & Wilkins, Baltimore.
19. Wafford KA and Ebert B (2008) Emerging anti-insomnia drugs: Tackling sleeplessness and the quality of wake time. Nat Rev Drug Discov 7:530-540.
20. Zammit G (2009) Comparative tolerability of newer agents for insomnia. Drug Saf 32:735-748.
21. Zisapel N (2012) Drugs for insomnia. Expert Opin Emerg Drugs 17:299-317.